Clario and Cogstate Expand Partnership to Provide Data Collection and Data Quality Programs for Neuroscience Clinical Trials | Business and finance

Collaboration Combines Clario’s eCOA Innovations with Cogstate’s Expertise in Neuroscience Research to Produce the Highest Quality Endpoints

  • Expanding Partnership Will Help Optimize Cognitive Neuroscience Assessments in Clinical Trials to Accelerate New Therapies to Market
  • Combines Clario’s innovative eCOA Multimedia technologies for audio and photo capture with Cogstate’s global clinical network and therapeutic area expertise
  • Offers both high data quality benefits and operational ease for patients and clinicians

PHILADELPHIA, May 20, 2022 /PRNewswire/ — Clario, a technology company that provides leading endpoint solutions for decentralized clinical trials (DCTs), hybrids and on-premises, announced today, on the Day Global Clinical Trials, an extension of its partnership with cognitive science company, Cogstate, to jointly provide data quality solutions to meet the unique requirements of neuroscience assessments for therapeutic development.

The collaboration improves data quality and signal detection for the full range of conventional cognitive parameters common in neuroscience studies. It combines Clario’s eCOA multimedia technology for audio, photo and patient/clinician data capture with Cogstate’s global clinical network and deep therapeutic expertise in neurodegenerative diseases. This expands the companies’ previously announced partnership to deliver Cogstate’s Digital Cognitive Assessments with Clario’s eCOA platform, providing a significantly streamlined solution for digital and conventional outcomes with an integrated approach to hardware, training and support. operational.

“Clinical trials, especially those involving neurodegenerative diseases, require sensitive and reliable endpoints that are delivered with a streamlined, patient-centered approach, integrating the range of clinical assessments across performance-based outcomes, reported by clinicians and reported by patients,” said Andrew Cooper, executive vice president, eCOA and Trial Enablement at Clario. “Fit-for-purpose eCOA functionality, such as photo and audio capture and advanced workflow and scoring automations, enables reliable and standardized data collection for cognitive endpoints when tightly coupled with training and oversight of cutting-edge evaluators. That’s what Cogstate and Clario have come together to deliver.”

“We are excited to expand our partnership with Clario’s eCOA experts to support the full range of cognitive and clinical assessments essential to neuroscience research,” said Brad O’Connor, CEO of Cogstate. “As a company, we have pioneered digital assessments of cognition as well as new delivery models for training assessors of conventional cognitive assessments. The effective balance of data quality benefits with operational ease can only be achieved when you combine deep domain expertise with capable and flexible clinical systems.This expanded collaboration offers an approach that can significantly reduce assessor and site burden while producing quality results. »

Clinical trials can transform and save lives. This partnership will continue to drive innovation for clinicians and patients. To learn more about Clario’s eCOA Multimedia, please visit the Clario website.

Cogstate Ltd (ASX: CGS) is a leading neuroscience technology company that optimizes brain health assessments to advance new drug development and enable earlier clinical insights into health. Cogstate technologies provide fast, reliable and highly sensitive computer-based cognitive testing and support electronic clinical outcome assessment (eCOA) solutions to replace costly, error-prone paper-based assessments with real-time data capture. For more than 20 years, Cogstate has proudly supported the cutting-edge research needs of biopharmaceutical companies and academic institutions, as well as the clinical care needs of physicians and patients around the world.

Clario is a leading technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotechnology and medical device partners. Through decentralized and on-site trials, our deep scientific expertise, global scale, and industry’s broadest endpoint technology platform enable our partners to transform lives. Clario’s Trial Anywhere™ solutions have powered hybrid and decentralized clinical trials (DCTs) for more than 15 years, enabling sponsors to collect high-quality endpoint data from any modality or location, while improving patient experience and diversity. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision movement and respiratory parameters. With 30 facilities in nine countries, Clario’s global team of science, technology and operational experts have helped deliver more than 19,000 trials and 870 regulatory approvals for more than 5 million patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.

Senior Director, Public Relations and Thought Leadership

Copyright © 2022 PR Newswire Association LLC. All rights reserved.

Comments are closed.